In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scrip Team

Latest From Scrip Team

Executives On The Move: CFO Promoted At Novavax, Gilead Gets New Executive Vice President Of Research

Alpha Cognition, F2G and Immune Pharmaceuticals pick up new CEOs, and there is a new chief medical officer at Gemini Therapeutics.

Appointments BioPharmaceutical

Coronavirus Update: J&J Vaccine On Pause Amid Reports Of Clots

The CDC and FDA recommended a pause on dosing of J&J's one-shot vaccine. Pfizer/BioNTech's vaccine showed signs of lower efficacy against the B.1.351 variant, but a prominent expert called the data "misleading." Gilead halted its Phase III study of Veklury in non-hospitalized, high-risk patients. And Rigel's Tavalisse may have a shot in the sickest COVID-19 patients despite the small size of a Phase II study.

United States Vaccines

The 2021 Scrip Awards Is Open For Entries

Entries for the Scrip Awards are now open. Now in their 17th year, the Awards seek to reward the outstanding achievements of the pharmaceutical, biotech and allied industries in improving human health and will take place in London on 2 December.

Companies Commercial

Executives On The Move: Executive Team Announced As Sawai Pharmaceuticals Transitions To New Holding Structure

New chief medical officers at AlzeCure Pharma, Eledon, Prothena and Tyme Technologies.

Appointments BioPharmaceutical

Coronavirus Update: CoVIg-19 Alliance Ends As Trial Misses Endpoints

Global research consortium to investigate the use of immunoglobulin as a COVID-19 therapy ends following disappointing results from a Phase III trial. Meanwhile, Russian vaccine producer RDIF is snapping up more production capacity in India, where interferon has also progressed as a possible treatment. 

Coronavirus COVID-19 Research & Development

Coronavirus Update: Pfizer/BioNTech Vaccine Shows Six-Month, Variant Protection

The companies still plan to develop a variant-specific version, while J&J said it anticipates meeting vaccine supply goals despite a manufacturing mix-up.

Coronavirus COVID-19 Research & Development
See All
UsernamePublicRestriction

Register